A new study shows that the weight-loss drug semaglutide not only reduces weight in older mice but also slows down their aging processes and extends their lifespan by about twelve percent. (translated)
A new study shows that semaglutide, a weight loss injection, not only extends the lifespan in mice but also reduces several biological age markers, indicating potential anti-aging potential. (translated)
A study shows that semaglutide, the active ingredient in Ozempic, outperforms intermittent fasting by slowing down aging and improving the quality of life of the treated mice, increasing their lifespan and restoring cognitive and physical functions. (translated)
GLP-1 drugs significantly extend lifespan in female mice when given late in life 👀 Semaglutide (Ozempic) also improved physiological function, suggesting it might mimic the effects of caloric restriction. https://t.co/ZSui5qjODd #GLP1 #Semaglutide #LifespanResearch #Therearenospecificcountrycodesrelevanttothistweet.
In Germany, the weight loss medication Wegovy is now also available in tablet form, with the article explaining the differences from the injection and important aspects of taking it. (translated)
The introduction of the weight loss pill containing the active ingredient semaglutide in Germany as the first EU country could bring significant changes for society and the approximately twelve million adults with obesity. (translated)
VAI TER MAGRA! Anvisa aprovou o primeiro genérico da semaglutida (Ozempic) no Brasil. O medicamento deve custar 35% menos que o Ozivy, o "Ozempic brasileiro". https://t.co/HW0Oj496pB #Saúde #Medicina #Genérico
🚨✊ NÃO VAI TER GORDA: Anvisa finalmente aprovou o genérico da semaglutida (Ozempic)! Agora a caneta emagrecedora queridinha das atrizes de Hollywood será comercializada no Brasil em versões bem mais baratas e acessíveis. https://t.co/5NISLDP10F #Semaglutida #Emagrecimento #Saúde
In Germany, a new weight loss medication in tablet form containing the active ingredient Semaglutide will be available for the first time starting September 1, 2026, which is approved for weight reduction in individuals with obesity or overweight, although it will only be available by prescription and the costs will initially have to be borne by the patients themselves. (translated)
A new type of weight loss tablet containing the active substance Semaglutide will soon be available in Austria, which has a similar effect to the already approved injection, but requires a higher active ingredient content and is primarily intended for people with overweight or obesity, while its use, side effects, and potential risks should be considered under medical supervision. (translated)
Pharmaceutical company Novo Nordisk will launch Wegovy tablets on the German market on September 1, 2026, which contain the same active ingredient Semaglutide as the currently available injectable forms, thus offering an alternative option for customers who avoid injections. (translated)
In 2025, spending on antidiabetic drugs also used for the treatment of obesity reached 1.59 billion euros in Italy, marking a 34.9% increase compared to the previous year, with a notable rise in the consumption of semaglutide and tirzepatide. (translated)
New weight loss drugs, such as the combination of tirzepatide and semaglutide, are effective in weight loss; however, they have significant side effects, including loss of muscle mass and gastrointestinal problems, which can affect patients' quality of life, which was not significantly improved in this study. (translated)
Novo istraživanje otkriva da lijekovi za mršavljenje iz skupine GLP-1 agonista, poput semaglutida i tirzepatida, mogu biti povezani s povećanim rizikom od ispadanja kose, iako uzročnost još nije potvrđena, a analiza prijava sugerira da bi uzrok mogla biti smanjena unos kalorija i fiziološki stres. #GLP-1agonisti #ispadanjekose #alopecija
O moleculă naturală descoperită cu ajutorul inteligenței artificiale, denumită BRP, ar putea reduce pofta de mâncare și greutatea corporală similar cu semaglutida din Ozempic, având totodată mai puține efecte secundare, conform cercetătorilor de la Stanford Medicine. #obezitate #Ozempic #inteligențaartificială
Un nuovo studio pubblicato sul British Medical Journal mostra che l'uso di farmaci anti-obesità come semaglutide e tirzepatide è associato a un aumento del rischio di alopecia, con una probabilità del 37% superiore rispetto ai farmaci SGLT-2 e del 68% rispetto ai farmaci DPP-4, sebbene i tassi effettivi di alopecia restino bassi. #AntiObesità #Alopecia #FarmaciDiabete
Die EU-Kommission hat die Zulassung für eine neue Abnehmpille mit dem Wirkstoff Semaglutid erteilt, die erstmals in Tablettenform erhältlich sein wird, nachdem sie zuvor als Spritze verabreicht wurde, und das Pharmaunternehmen Novo Nordisk plant schrittweise die Einführung in den EU-Ländern. #Adipositas #Abnehmpille #Semaglutid
Die EU hat die erste orale „Abnehmpille“ mit dem Wirkstoff Semaglutid zugelassen, die ähnlich wie die bisherige Abnehmspritze funktioniert und für Menschen mit starkem Übergewicht oder Übergewicht mit Begleiterkrankungen vorgesehen ist, jedoch tägliche Einnahme erfordert und unter ärztlicher Begleitung erfolgen sollte. #Abnehmpille #Wegovy #Übergewicht
Uno studio recente pubblicato su BMJ Open ha rivelato che i farmaci a base di semaglutide e GLP-1, inizialmente sviluppati per il trattamento del diabete e dell'obesità, possono ridurre i ricoveri ospedalieri per alcolismo fino al 65%, evidenziando un potenziale nuovo uso terapeutico per combattere la dipendenza da alcol. #Alcolismo #GLP1 #Semaglutide
L'EMA ha approvato la semaglutide in compresse da 25 mg, commercializzata come Rybelsus, come primo trattamento orale per la gestione del peso in Europa, indicata per adulti con diabete di tipo 2 non controllato, con posologia che inizia a 3 mg al giorno e può arrivare fino a un massimo di 50 mg. #Semaglutide #Rybelsus #DiabeteTipo2
